| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2014: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Outline of Final Research Achievements |
The prevention of relapse and infection complications during remission maintenance therapy is required to improve the prognosis of patients with rapidly progressive glomerulonephritis (RPGN). The clinicopathological characteristics of patients with RPGN were examined to determine the risk factors for relapse or infectious complications after remission induction therapy.
As results of this study, the relation of organ damage severity at remission to relapse has been shown for patients with RPGN. In addition, disease activity at diagnosis and severity of organ damage at remission are related to infectious complications. Further investigations of treatment methods for patients with high disease activity at diagnosis and severe organ damage at remission are required to further improve the prognosis of RPGN patients.
|
